GABA — Gamma-Aminobutyric Acid — is the brain's primary inhibitory neurotransmitter. Its job is the brake pedal. When GABA activity rises, neuronal excitability drops. The internal noise quietens. Anxiety loosens. The social self becomes available. This is precisely what a glass of wine does. Alcohol doesn't create a unique feeling. It hijacks an existing one.

Ethanol floods the GABA system. That's the warmth. That's the sudden interest in the person next to you. But ethanol is a blunt instrument. It taxes the liver, wrecks sleep architecture, depletes B vitamins, inflames the gut — and then, as it metabolises through the night, triggers a rebound in neurological excitability. The thing that made the evening feel expansive makes the morning feel like a verdict.

Sentia's design is to stimulate the GABA pathway using botanical compounds that work more selectively, and without ethanol's collateral damage. The key ingredients: valerian root, used in herbal medicine for centuries as a mild sedative; ashwagandha, the Ayurvedic adaptogen with documented anxiolytic properties; and passionflower, shown in multiple studies to interact with GABA receptors in ways that produce calm without sedation at moderate doses.

This is not folklore dressed in lab coat language. The botanical interactions with GABA receptors are real and measurable. What is less certain — and what mixed consumer reviews confirm — is how reliably and how strongly those interactions translate in a drink format, given individual variation in neurochemistry, body weight, tolerance, and expectation.

The science is credible. The experience varies.

Professor David Nutt seems constitutionally unable to soften conclusions for political convenience. As chair of the UK Advisory Council on the Misuse of Drugs, he published peer-reviewed evidence in 2009 placing alcohol and tobacco as more harmful to individuals and society than MDMA, LSD, and cannabis. The Home Secretary sacked him within days.

Most people, publicly humiliated by a government for being correct, retreat into academic caution. Nutt did something more interesting. He took his research into the GABA system and founded GABA Labs — a company built to turn decades of neuropharmacological insight into consumer products. Sentia is GABA Labs' first range: three botanical spirits (Red, Black, and Gold), calibrated for different social occasions.

But Sentia is, by Nutt's own account, the prototype. His longer project — Alcarelle — aims to synthesise a specific GABA-modulating molecule that could be added to any drink. Precise. Dose-controlled. Alcohol-like experience, without the toxicity. The ambition is not small. Nutt has spoken openly about wanting to replace alcohol entirely, or at least to offer a genuine alternative that operates on the same social register.

Consider the structure of what that would disrupt. The global drinks industry moves hundreds of billions of pounds annually. The hangover economy — paracetamol, rehydration sachets, Sunday brunch trade — is built on ethanol's after-effects. A safe, legal, effective substitute is not a wellness product. It is a structural disruption to one of the most entrenched commercial ecosystems on earth.

That the man driving it was ejected from government for inconvenient truths about alcohol is not incidental. It is the whole shape of the story.

Reviews of Sentia are numerous enough now to show patterns. Those patterns are genuinely mixed — and the mixed-ness is itself informative.

The Independent described Sentia as "Star Trek's synthehol come to life." Several reviewers report a real, noticeable shift: mild warmth, loosening of social tension, a gentle relaxation arriving without ethanol's accompanying fog. These accounts tend to cluster around Sentia Red. Sentia Black draws more ambivalent responses — effects described as subtle to imperceptible.

The Evening Standard assembled sceptical testers. Some felt a lift within ten to twenty minutes. Others felt nothing but mild nausea. Taste became a sticking point — "medicinal," "herbal," "pharmacy-like" appear repeatedly. Sentia Red improves significantly with tonic water or ginger beer. Sentia Black is earthier and spicier, more acquired.

A longer test by a father-and-son pair found effects became noticeable only after four to five measures — a relaxed, talkative sociability both described as resembling early drinking, without the weight of intoxication. Neither felt drunk. Both felt different.

These accounts surface a question that is genuinely hard to resolve. How much of this is pharmacology, and how much is placebo? The expectation of effect — built by reading about GABA systems, paying a premium price, performing the ritual of mixing and serving — is itself neurologically active. Expectation triggers dopamine. Social context modulates anxiety. The act of choosing a conscious alternative may itself be part of what produces the shift.

This does not necessarily undermine Sentia. Placebo is one of the most powerful and consistent phenomena in medicine. But it complicates the claim that a specific molecular interaction is responsible for what drinkers report. The honest answer is probably: both.

Sentia is not arriving in a vacuum. A significant cultural shift in attitudes toward alcohol is now statistically undeniable.

Gen Z — those born roughly between the mid-1990s and early 2010s — are drinking substantially less than any generation in recent recorded history. UK surveys consistently show a higher proportion of young adults identifying as non-drinkers than at any point in the past fifty years. The same pattern holds in the United States. The reasons are multiple and contested: mental health awareness, social media replacing bar culture as a social venue, economic pressure, fitness culture, greater drug literacy. The direction of travel is not contested.

The sober curious movement, popularised by writer Ruby Warrington and institutionalised by Dry January and Sober October, has moved from fringe to mainstream. London now has multiple thriving alcohol-free bars. Premium non-alcoholic spirits — Seedlip, Lyre's, Sentia — have moved from health food shelves to high-end cocktail menus.

What makes Sentia distinct in this landscape is that it doesn't merely replicate the taste of a cocktail without the alcohol. It targets the feeling — the neurological state — that people are actually after. Most alcohol-free alternatives are sophisticated cordials. They taste like a drink. They don't do anything. Sentia explicitly attempts to do something. To cross the line from beverage into mild psychoactive.

That distinction is meaningful. And it opens questions that the industry, regulators, and consumers are only beginning to sit with.

Step back far enough, and Sentia belongs to a tradition older than civilisation as we conventionally date it.

Every culture that has left archaeological traces has also left evidence of psychoactive plant use. Fermented beverages, smoked herbs, infused teas, sacred brews administered in ritual contexts to shift awareness, facilitate healing, commune with the divine, or simply strengthen social bonds. The ancient Greeks had kykeon — the grain-based drink consumed during the Eleusinian Mysteries, possibly containing ergot compounds with psychedelic properties. The Vedic tradition speaks of soma, an unidentified sacred drink granting divine vision. Indigenous Amazonian cultures have prepared ayahuasca — a botanical combination activating serotonin receptors — for healing ceremonies for thousands of years.

The impulse behind all of these is recognisable in Sentia's design: use plant chemistry to modulate neurological states for better social, spiritual, or psychological outcomes. The technological sophistication differs. The underlying aspiration does not.

Ashwagandha's presence in Sentia quietly carries this history. Withania somnifera has been used in Ayurvedic medicine for over three thousand years — prescribed for anxiety, fatigue, and cognitive clarity. Its inclusion in a modern GABA spirit is not a marketing accident. It is a direct inheritance from a knowledge system that was mapping the nervous system's botanical pharmacopoeia millennia before the word neuroscience existed. Valerian root appears in ancient Greek and Roman medical texts. Passionflower was used by indigenous peoples of the Americas before it appeared in European herbal pharmacopeias.

What Sentia does, in this longer frame, is repackage ancient botanical intelligence in the grammar of contemporary neuroscience. Whether you find that reductive or clarifying probably says something about how you hold the relationship between tradition and modernity.

The sharper question is whether intentionality can survive the bottling process. When a shaman prepares an ayahuasca ceremony, the set, the setting, the intention, the community — these are as much the medicine as the brew. When Sentia is poured into a glass at a cocktail party in east London, most of that scaffolding is absent. Does it matter? Can a modern drinker recreate something of that frame through conscious choice — by deciding why they are altering their state, and what they hope to find there? These are not questions Sentia's marketing team will answer. They may be the most important questions the drink raises.

Sentia is sold as a food supplement. Not a pharmaceutical. Not an alcohol product. In the UK and most markets where it operates, this means food safety standards apply — but not the more stringent requirements of licensed medicines. It comes with recommended daily limits, an acknowledgment that it is doing something pharmacologically. It does not come with clinical trial data.

This is not necessarily a scandal. Coffee, kava, valerian tea, St. John's Wort — many substances consumed daily occupy similar grey zones. But the precise dose-response relationship for Sentia's effects is not as well characterised as it would be for a licensed drug. Individual variation in body weight, liver enzyme activity, existing GABA sensitivity, and concurrent medication is real and consequential.

There is also the question of long-term use. GABA-system modulation through exogenous substances is not neutral over time. Benzodiazepines — pharmaceutical GABA agonists — carry well-documented risks of tolerance and dependence when used regularly. Sentia's botanical compounds are far milder and work through different mechanisms. But the principle of neuroadaptation — the brain adjusting its baseline GABA sensitivity in response to regular stimulation — is worth holding. Nutt's team is presumably aware of this; it is likely central to how they are approaching Alcarelle. But the long-term picture for regular Sentia consumers is not yet known.

Some reviewers have noted strong cravings to consume more after the first serving. That observation deserves attention rather than dismissal. Whether it reflects genuine psychoactive signal — the brain recognising and wanting more of a GABA-enhancing input — or social conditioning, or simple enjoyment, is unclear. But asking whether a product designed as a safer alternative to an addictive substance could itself carry dependency potential is not irresponsible. It is the correct question.

Sentia is, in all probability, substantially safer than ethanol for most people in normal use. A few deliberate servings at a dinner party is a different relationship with a substance than a daily crutch. But honest framing requires acknowledging open questions alongside the genuine promise.

Professor Nutt's project is fundamentally a scientific one: reduce harm, preserve the experience. But the experience may not be separable from the harm in the ways we assume.

Sacred plant traditions understood this. The medicine and the discomfort were often the same thing. The difficulty was the point. Ayahuasca ceremonies are not comfortable. Kykeon was taken at the threshold of something terrifying. The ordeal and the insight arrived together, not separately packaged for consumer preference.

If Alcarelle eventually produces a molecule precise enough to be prescribed — take this much for the sociable warmth of two drinks; take this much for the calm of a quiet evening — what happens to the serendipity of intoxication? The slightly too much. The unexpected depth of a conversation. The loss of control that sometimes, against expectation, produces something true. Is the unpredictability of alcohol, for all its costs, part of what we're actually seeking?

A frictionless GABA drink may be useful, safer, and genuinely different in kind from what it replaces. Not better or worse. Different. The ritual of choosing it deliberately — picking Sentia over wine, deciding to examine what you actually want from the evening — may carry more of the real work than any botanical formula. Ancient traditions did not just administer a brew. They asked why you were there, and what you were willing to face. That question did not come in a bottle. It came before you opened one.